Key facts
- Freedom Biosciences’s last known valuation is $60.8M (Mar 2025).
- It has raised $27.8M; the latest was Early Stage VC ($17.3M) in Mar 2025.
- Notable investors include Gaingels, Evolution VC Partners, Village Global, Unruly Capital, MBX Capital — 21 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 21 names
- ·Watchlist + deal alerts for Freedom Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Freedom Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Freedom Biosciences
Developer of a biotechnology platform designed for next-generation psychedelic therapeutics. The company offers ketamine-based therapies and combinations of neuropsychiatric drugs to create neuropsychiatric treatments for mental health and substance use disorders, enabling patients suffering from depression, PTSD, and other disorders to access more effective and safer treatment options.
- Sector
- Healthcare
- HQ
- Tiburon, CA, United States
- Founded
- 2021
- Employees
- 8
- Website
- freedombio.co/
- Ownership
- Privately Held (backing)
Freedom Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Freedom Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Freedom Biosciences in its N-PORT filings yet. We sweep new filings monthly.